Corbus Pharmaceuticals Holdings Inc
NASDAQ:CRBP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Corbus Pharmaceuticals Holdings Inc
NASDAQ:CRBP
|
US |
|
E
|
Everest Medicines Ltd
HKEX:1952
|
CN |
Balance Sheet
Balance Sheet Decomposition
Corbus Pharmaceuticals Holdings Inc
Corbus Pharmaceuticals Holdings Inc
Balance Sheet
Corbus Pharmaceuticals Holdings Inc
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
1
|
0
|
6
|
12
|
15
|
63
|
42
|
32
|
85
|
25
|
17
|
14
|
17
|
28
|
|
| Cash |
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
2
|
7
|
4
|
4
|
5
|
1
|
|
| Cash Equivalents |
1
|
0
|
6
|
12
|
14
|
62
|
41
|
31
|
84
|
18
|
13
|
10
|
12
|
27
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
73
|
42
|
7
|
132
|
135
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
3
|
3
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
1
|
3
|
3
|
4
|
4
|
3
|
1
|
3
|
4
|
4
|
|
| Total Current Assets |
1
|
0
|
7
|
13
|
17
|
66
|
44
|
38
|
92
|
100
|
60
|
24
|
153
|
167
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
1
|
3
|
11
|
9
|
7
|
6
|
4
|
3
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
1
|
3
|
11
|
9
|
7
|
6
|
4
|
3
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
3
|
4
|
4
|
4
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
|
| Total Assets |
1
N/A
|
0
-40%
|
7
+2 100%
|
13
+95%
|
18
+39%
|
67
+274%
|
47
-30%
|
49
+4%
|
102
+108%
|
108
+5%
|
66
-38%
|
28
-57%
|
156
+451%
|
168
+8%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
0
|
0
|
0
|
1
|
3
|
3
|
6
|
11
|
7
|
2
|
2
|
3
|
5
|
2
|
|
| Accrued Liabilities |
0
|
0
|
0
|
1
|
3
|
5
|
10
|
23
|
23
|
11
|
7
|
12
|
7
|
18
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
4
|
3
|
16
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
2
|
2
|
0
|
2
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
0
|
1
|
1
|
4
|
9
|
8
|
18
|
35
|
32
|
17
|
13
|
32
|
12
|
21
|
|
| Long-Term Debt |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
18
|
16
|
16
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
8
|
7
|
6
|
5
|
3
|
2
|
0
|
|
| Total Liabilities |
1
N/A
|
1
+43%
|
1
-30%
|
4
+457%
|
9
+131%
|
9
+2%
|
20
+112%
|
43
+121%
|
57
+33%
|
39
-32%
|
33
-14%
|
35
+6%
|
13
-62%
|
21
+54%
|
|
| Equity | |||||||||||||||
| Common Stock |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
1
|
2
|
4
|
13
|
33
|
66
|
121
|
193
|
304
|
350
|
392
|
437
|
477
|
555
|
|
| Additional Paid In Capital |
0
|
0
|
10
|
22
|
42
|
124
|
149
|
199
|
349
|
419
|
425
|
430
|
619
|
703
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
0
N/A
|
1
-250%
|
6
N/A
|
9
+53%
|
9
-1%
|
58
+549%
|
28
-52%
|
6
-77%
|
45
+631%
|
69
+53%
|
33
-52%
|
7
N/A
|
142
N/A
|
148
+4%
|
|
| Total Liabilities & Equity |
1
N/A
|
0
-40%
|
7
+2 100%
|
13
+95%
|
18
+39%
|
67
+274%
|
47
-30%
|
49
+4%
|
102
+108%
|
108
+5%
|
66
-38%
|
28
-57%
|
156
+451%
|
168
+8%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
3
|
4
|
4
|
4
|
12
|
18
|
|